Journal
PHARMACEUTICALS
Volume 15, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/ph15080936
Keywords
systemic lupus erythematosus; systemic sclerosis JAK inhibitors; cytokine network
Categories
Funding
- Medical University of Silesia Katowice, Poland
Ask authors/readers for more resources
Systemic sclerosis and systemic lupus erythematosus are two distinct autoimmune diseases belonging to connective tissue disorders, with no groundbreaking therapeutic approaches developed yet. The discovery of JAK kinases may offer a new therapeutic potential for previously untreatable diseases.
Systemic sclerosis and systemic lupus erythematosus represent two distinct autoimmune diseases belonging to the group of connective tissue disorders. Despite the great progress in the basic science, this progress has not been translated to the development of novel therapeutic approaches that can radically change the face of these diseases. The discovery of JAK kinases, which are tyrosine kinases coupled with cytokine receptors, may open a new chapter in the treatment of so far untreatable diseases. Small synthetic compounds that can block Janus kinases and interact directly with cytokine signalling may provide therapeutic potential in these diseases. In this review, we discuss the therapeutic potential of Jak kinases in light of the cytokine network that JAK kinases are able to interact with. We also provide the theoretical background for the rationale of blocking cytokines with specific JAK inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available